. . . . . . . "[A phase I trial of intravesical recombinant adenovirus mediated interferon-?2b gene therapy (rAd-IFN?) formulated with the excipient SCH Syn3 was conducted in patients with nonmuscle invasive bladder cancer who had disease recurrence after treatment with bacillus Calmette-Gu�rin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:14:58+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .